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Untangling the clinicopathological significance of
MRE11-RAD50-NBS1 complex in sporadic breast cancers
Adel Alblihy1,2,6, Ahmed Shoqafi1,6, Michael S. Toss1,3, Mashael Algethami1, Anna E. Harris 1, Jennie N. Jeyapalan1, Tarek Abdel-Fatah4,
Juliette Servante5, Stephen Y. T. Chan4, Andrew Green1, Nigel P. Mongan1, Emad A. Rakha1,3 and Srinivasan Madhusudan 1,4✉
The MRE11–RAD50–NBS1 (MRN) complex is critical for genomic stability. Although germline mutations in MRN may increase breast
cancer susceptibility, such mutations are extremely rare. Here, we have conducted a comprehensive clinicopathological study of
MRN in sporadic breast cancers. We have protein expression profiled for MRN and a panel of DNA repair factors involved in double-
strand break repair (BRCA1, BRCA2, ATM, CHK2, ATR, Chk1, pChk1, RAD51, γH2AX, RPA1, RPA2, DNA-PKcs), RECQ DNA helicases
(BLM, WRN, RECQ1, RECQL4, RECQ5), nucleotide excision repair (ERCC1) and base excision repair (SMUG1, APE1, FEN1, PARP1,
XRCC1, Pol β) in 1650 clinical breast cancers. The prognostic significance of MRE11, RAD50 and NBS1 transcripts and their microRNA
regulators (hsa-miR-494 and hsa-miR-99b) were evaluated in large clinical datasets. Expression of MRN components was analysed in
The Cancer Genome Atlas breast cancer cohort. We show that low nuclear MRN is linked to aggressive histopathological
phenotypes such as high tumour grade, high mitotic index, oestrogen receptor- and high-risk Nottingham Prognostic Index. In
univariate analysis, low nuclear MRE11 and low nuclear RAD50 were associated with poor survival. In multivariate analysis, low
nuclear RAD50 remained independently linked with adverse clinical outcomes. Low RAD50 transcripts were also linked with
reduced survival. In contrast, overexpression of hsa-miR-494 and hsa-miR-99b microRNAs was associated with poor survival. We
observed large-scale genome-wide alterations in MRN-deficient tumours contributing to aggressive behaviour. We conclude that
MRN status may be a useful tool to stratify tumours for precision medicine strategies.
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INTRODUCTION
The MRE11–RAD50–NBS1 complex (MRN), a chemo-mechanical
molecular machine, is critical for the maintenance of genomic
stability1–3. MRN is required not only for processing DNA damage
but also for oncogene-induced replication stress. MRN is a
hexameric complex consisting of two RAD50 subunits (ATPase
activity), two MRE11 subunits (DNA structure-specific endo- or
exonuclease activity) and two NBS1 subunits (a regulatory docking
protein with phosphopeptide-interacting forkhead-associated and
BRCA1 C-terminal domains flexibly linked to an MRE11 interface
and adjacent C-terminal ATM kinase interaction motif). The
interaction of MRE11, RAD50 and NBS1 together promote MRN
complex stability1–3.
MRN is recruited by RAD17 to sites of double-strand breaks
(DSBs), which activates it4. MRN activates ataxia-telangiectasia-
mutated (ATM) kinase, which in turn phosphorylates more than
700 proteins. ATM-induced CHK2 phosphorylation coordinates
checkpoint signalling5,6. During homologous recombination
repair (HR), MRN initiates the 5′ resection, which is followed by
further resection by EXO1 or DNA2 nuclease. The resulting 3′
single-strand DNA (ssDNA) overhangs are loaded with replication
protein A (RPA). Ataxia-telangiectasia and RAD3-related (ATR) is
then recruited to RPA-coated ssDNA. Activated ATR, in turn,
phosphorylates CHK1, which contributes to cell cycle regulation.
During HR, the BRCA2–RAD51 complex nucleates the formation
of RAD51 nucleofilaments and later displaces RPA from ssDNA.
RAD51 nucleofilaments then promote homology search and
strand invasion in association with BRCA1–BARD1 for error-free
repair through the resolution of repair intermediates. Although
classical NHEJ does not require MRN, microhomology-mediated
end-joining operates through MRN–CtIP-mediated resection,
followed by priming based on microhomology, flap removal
and gap filling1–3.
Germline mutations in MRE11, NBS1 or RAD50 can cause
genomic instability syndromes characterized by immunodefi-
ciency, hypersensitivity to radiation and cancer predisposition7,8.
Mutations in the MRE11 cause ataxia-telangiectasia-like disor-
der9. Mutation in NBS1 can cause Nijmegen breakage syndrome
(NBS)7. RAD50 deficiency has also been reported in a case of
NBS-like disorder8. Polymorphic variation in MRE11, RAD50 and
NBS1 genes may increase cancer risk including breast cancer
predisposition10–12. However, the clinicopathological significance
of MRN in human sporadic breast cancers has not been clearly
defined. In the current study, we have used immunohistochem-
istry (IHC) to examine the expression of MRN and other factors
involved in DSB repair (BRCA1, BRCA2, ATM, CHK2, ATR, CHK1,
pCHK1, RAD51, γH2AX, RPA1, RPA2, DNA-PKcs), RECQ helicases
(BLM, WRN, RECQ1, RECQL4, RECQ5), nucleotide excision repair
(ERCC1) and base excision repair (SMUG1, APE1, FEN1, PARP1,
XRCC1, Pol β) in a large clinical cohort of 1650 breast cancers.
Detailed bioinformatics of MRN interactors at the transcriptomic
level as well as the prognostic value of MRE11 mRNA, RAD50
mRNA, NBS1 mRNA expressions and their microRNA (miRNA)
regulators (hsa-miR-494 and hsa-miR-99b) were evaluated in large
clinical datasets.
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MRN and histopathological features
We initially tested MRE11, RAD50 and NBS1 protein expression in a
panel of breast cancer cell lines [MCF-7 (ER+, luminal A), ZR-75-1
(ER+, luminal B), SKBR3 (HER2+), MDA-MB-231 (triple-negative)].
As shown in Fig. 1a, MCF-7 and MDA-MB-231 showed robust
expression of MRE11, RAD50 and NBS1. On the other hand, ZR-75-
1 and SKBR3 had low MRE11, RAD50 and NBS1 protein expression.
We proceeded to an immunohistochemical evaluation in a clinic
cohort of 1650 breast cancers.
We observed nuclear and cytoplasmic MRE11 expression in
breast cancers (Fig. 1b). As the nuclear level of MRE11 primarily
contributes to DDR function, we first evaluated nuclear MRE11 and
correlated to histopathological features. The data are summarized
in Table 1. Low nuclear MRE11 [46% (302/659)] was strongly
associated with aggressive clinicopathological features including
high tumour grade, high mitotic index, de-differentiation, marked
pleomorphism, HER2+, oestrogen receptor (ER)- and high-risk
Nottingham Prognostic Index (NPI) phenotypes (all p < 0.01).
Cytoplasmic staining of MRE11 [54% (357/659)] was associated
with low-grade tumours (p= 0.01) with reduced pleomorphism
(p= 0.01) (Supplementary Table 3).
We also observed nuclear and cytoplasmic staining for NBS1
(Fig. 1b). Low nuclear NBS1 [48% (565/1166)] was associated with
larger tumours, higher grade, high mitotic index, marked
pleomorphism, ER- and high-risk NPI phenotypes (all p < 0.01).
Low cytoplasmic NBS1 [48% (565/1166)] was associated only with
de-differentiation (p < 0.001) (Supplementary Table 3).
We observed nuclear-only staining for RAD50 expression
(Fig. 1b). Low nuclear RAD50 [46% (339/733)] was highly
associated with high tumour grade, high mitotic index, ER- and
high-risk NPI phenotypes (all p values < 0.01) (Table 1).
Taken together, the data suggest that low MRN protein levels
may contribute to aggressive histopathological features in
breast cancer.
MRN and correlation to other DNA repair proteins
Given the critical role played by MRN in DDR and the interaction with
several DNA repair proteins in multiple pathways1–3, we correlated
MRN expression with other proteins involved in DSB repair (BRCA1,
BRCA2, ATM, CHK2, ATR, Chk1, pChk1, RAD51, γH2AX, RPA1, RPA2,
DNA-PKcs), RECQ helicases (BLM, WRN, RECQ1, RECQL4, RECQ5),
nucleotide excision repair (ERCC1) and base excision repair (SMUG1,
APE1, FEN1, PARP1, XRCC1, Pol β) in the breast cancer cohort. The
data are summarized in Supplementary Table 4. We observed a
strong association between MRE11 and several DNA repair proteins
(Fig. 1c), including RAD50, NBS1, BCRA1, ATM, CHK2, CHK1, pCHK1,
RAD50, RAD51, γH2AX, RPA1, DNA-PKcs, BLM, RECQL1, RECQ4,
RECQ5, ERCC1, SMUG1 and POLβ (all p values < 0.05, full data shown
in Supplementary Tables 4 and 5 and Supplementary Data 1). A
significant association between RAD50 and NBS1, BCRA1, CHK2, ATR,
CHK1, pCHK1, RAD51, γH2AX, RPA1, RPA2, DNA-PKcs, BLM, RECQL1,
RECQ4, RECQ5, ERCC1, SMUG1, PARP1 and POLβ was also evident (all
p values < 0.05, full data shown in Supplementary Tables 4 and 5 and
Supplementary Data 1). Similarly, significant association between
NBS1 and BCRA1, ATM, CHK2, CHK1, pCHK1, RAD51, γH2AX, RPA1,
DNA-PKcs, BLM, RECQL1, RECQ5, SMUG and POLβ was observed (all
p values < 0.05, full data shown in Supplementary Tables 4 and 5 and
Supplementary Data 1).
Together, the data provide evidence that low nuclear MRN is
associated with reduction in the level of other key DNA repair
proteins in a proportion of breast cancers, which together could
contribute to aggressive histopathological phenotypes. We
proceeded to evaluate the prognostic significance of MRN in
breast cancer.
Fig. 1 MRN expression in breast cancers. aWestern blot showing MRE11, RAD50 and NBS1 protein expression in a panel of breast cancer cell
lines. All blots derive from the same experiment and they were processed in parallel. b Photomicrographs showing immunohistochemical
staining of MRE11, RAD50 and NBS1 in breast cancers. c Correlation Matrix showing the correlation between levels of MRE11, NBS1 and RAD50
protein expressions and other DNA repair biomarkers. Blue colour refers to positive (+) correlation, while the red colour reflects negative (−)
correlations. The size of the circles and intensity of the colour propionate to the correlation coefficient. The image was generated using
RStudio software. Red arrow = proteins investigated in the current study i.e. MRE11, RAD50 and NBS1.
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Low nuclear MRE11 was significantly associated with poor breast
cancer-specific survival (BCSS) (p= 0.002) (Fig. 2a). In the ER+
cohort, similarly, low nuclear MRE11 was strongly linked with poor
BCSS (p= 0.00006) (Fig. 2b) but not in ER− tumours (p= 0.121)
(Fig. 2c). Cytoplasmic expression of MRE11 did not influence
survival (Supplementary Fig. 1a–c). Low nuclear RAD50 was
significantly associated with poor BCSS (p= 0.0001) (Fig. 2d). In
the ER+ cohort, similarly, low nuclear RAD50 was also significantly
linked with poor BCSS (p= 0.0002) (Fig. 2e) but not in ER−
tumours (p= 0.370) (Fig. 2f). For NBS1, both nuclear (Fig. 2g–I) and
cytoplasmic expression did not significantly influence survival
(Supplementary Fig. 1D–F). When MRE11, RAD50 and NBS1 were
combined, we observed that survival in patients whose tumours
had low MRE11/low RAD50/low RAD50 was significantly lower
compared to patients whose tumours had high MRE11/high
RAD50/high RAD50 expression (Supplementary Fig. 2). In multi-
variate analysis, low nuclear RAD50 remained independently
associated with BCSS in the whole cohort and in ER+ cohort but
not in ER− cohort (Supplementary Table 6). The prognostic
significance of RA50 expression was also independent of ER status
in breast tumours (Supplementary Table 7). Taken together, the
data imply that altered subcellular localization with reduced
nuclear expression of MRN influence aggressive histopathological
phenotype and survival outcomes.
We then explored if a sub-group of tumours may also have a
complete loss of MRN expression [defined as nuclear H-score=
0 and cytoplasmic H-score= 0] by other mechanisms in the
breast cancer cohort. As shown in Supplementary Table 8,
although rare, we observed a complete loss of MRE11
expression in 14% (90/659) of tumours, complete loss of
RAD50 expression in 5% (40/733) of tumours and complete
loss of NBS1 expression in 9% (109/1166) of tumours. The data
suggest that besides altered subcellular localization, complete
loss of expression of MRN through mechanisms such as gene
deletion, epigenetic silencing, miRNA regulation or post-
translational mechanisms may also influence MRN expression
and survival. To explore this possibility, we evaluated publicly
available genomics datasets.
MRE11, RAD50 and NBS1 transcripts and survival
In a cohort of 1809 breast tumours (cohort 1), low RAD50 mRNA
was significantly associated with poor survival in the whole cohort
(p= 0.00061, Fig. 3a) and ER− cohort (p= 0.011, Fig. 3c). but not
in ER+ cohort (p= 0.13, Fig. 3b). In further cohort of 4904 tumours
(cohort 2), low RAD50 mRNA was significantly associated with poor
survival in the whole cohort (p= 0.01; Supplementary Figure 3A),
ER+ cohort (p= 0.03; Supplementary Fig. 3B) but not in ER−
cohort (p= 0.91; Supplementary Fig. 3C). MRE11 transcript level
Table 1. MRN complex protein expression and clinicopathological features in breast cancer.
MRE11 (nuclear) expression RAD50 (nuclear) expression NBS1 (nuclear) expression
Low High P value Low High P value Low High P value
Variable N (%) N (%) N (%) N (%) N (%) N (%)
Tumour size
≤2 cm 150 (42) 204 (58) 0.055 165 (43) 217(57) 0.084 223 (44) 287 (56) 0.004
>2 cm 152 (49.8) 153 (50.2) 174 (50) 177 (50) 342 (52) 314 (48)
Nottingham Prognostic Index (NPI)
1 64 (18) 112 (37) 84 (58) 11 9 (34) 131 (26) 230 (35)
2 217 (61) 155 (51) <0.001 228 (60) 184 (52) 0.001 285 (56) 327 (50) 0.002
3 73 (21) 38 (12) 70 (18) 48 (14) 94 (18) 99 (15)
Tumour grade
G1 27 (8) 60 (20) <0.001 45 (12) 61 (17) <0.001 75 (15) 120 (18) <0.001
G2 100 (28) 127 (42) 112 (29) 146 (42) 148 (29) 251 (38)
G3 226 (64) 118 (39) 223 (59) 144 (41) 288 (56) 284 (44)
Mitotic index
M1 (low; mitoses < 10) 71 (21) 126 (43) <0.001 88 (24) 144 (42) <0.001 152 (31) 240 (38) 0.002
M2 (medium; mitoses 10–18) 72 (21) 66 (22) 80 (22) 71 (21) 85 (17) 131 (21)
M3 (high; mitosis > 18) 199 (58) 102 (35) 198 (54) 125 (37) 256 (52) 260 (41)
Tubule formation
1 (>75% of definite tubule) 10 (3) 16 (5) 0.004 11 (3) 20 (6) 0.107 32 (7) 33 (5) 0.547
2 (10–75% definite tubule) 97 (28) 113 (38) 120 (33) 120 (35) 164 (33) 224 (36)
3 (<10% definite tubule) 235 (69) 165 (56) 235 (64) 200 (59) 197 (60) 374 (59)
Pleomorphism
1 (small-regular uniform) 2 (0.6) 12 (4) <0.001 5 (1) 9 (3) 0.063 9 (2) 19 (3) <0.001
2 (moderate variation) 95 (30) 128 (44) 121 (33) 135 (40) 154 (31) 277 (44)
3 (marked variation) 244 (72) 154 (52) 240 (66) 195 (57) 329 (67) 334 (53)
Her2 overexpression
No 273 (80) 70 (20) <0.001 310 (84) 61 (16) 0.077 415 (86) 67 (14) 0.525
Yes 269 (91) 28 (9) 299 (88) 40 (12) 548 (87) 79 (13)
ER/PR expression status
ER−/PR− 114 (33) 45 (15) <0.001 110 (30) 63 (19) 0.003 148 (30) 121 (19) <0.001
ER−/PR+ 0 (0) 0 (0) 0 (0) 1 (0) 0 (0) 1 (0)
ER+/PR− 56 (16) 47 (16) 64 (17) 54 (16) 80 (16) 115 (18)
ER+/PR+ 175 (51) 204 (69) 199 (53) 219 (65) 260 (53) 395 (63)
Bold values indicate statistical significance p values.
A. Alblihy et al.
3
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2021)   143 
(Supplementary Fig. 4) or NBS1 transcript level (Supplementary
Fig. 5) did not influence survival.
MRN miRNA regulators and survival
miRNAs are small, highly conserved non-coding RNA molecules
that can regulate gene expression. Emerging evidence indicates
that hsa-miR-99b and hsa-miR-494 miRNAs13 are involved in the
regulation of expression of RAD50, MRE11 and NBS1 transcripts.
The prognostic significance of hsa-miR-494 and hsa-miR-99b
was evaluated in a publicly available miRNA expression dataset
from 2178 breast cancer patients. High hsa-miR-99b was
significantly associated with poor survival in the whole cohort
(p < 0.0001; Fig. 3d), ER+ cohort (p < 0.0001; Fig. 3e) and ER−
cohort (p= 0.001; Fig. 3f). High hsa-miR-494 was also signifi-
cantly linked with poor survival in the whole cohort (p= 0.0001;
Fig. 3g), ER+ cohort (p= 0.0022; Fig. 3h) but not in ER− cohort
(p= 0.11; Fig. 3I).
Together, the data suggest that the transcriptional regulation of
MRN expression in a proportion of tumours may have prognostic
significance in breast cancer.
MRN and genome-wide expression levels
Besides a role in DDR, MRN is also essential for countering
oncogene-driven replication stress, dysfunctional telomeres and
regulation of innate immune response, thereby contributing to
overall cellular homeostasis1–3. MRN–ATM axis is also involved in
pro-survival signalling, epithelial–mesenchymal transition (EMT),
invasion and migration14,15. The multifunctional role of the MRN
network would imply that either its downregulation or over-
expression is likely to have far-reaching consequences at the
genome-wide level ultimately promoting or preventing cancer
development and prognosis. To explore this hypothesis, we
conducted bioinformatics investigations in The Cancer Genome
Atlas (TCGA) breast cancer (BRCA) cohort16,17.
Few coding variants were identified in MRE11, RAD50 and NBS1,
whereas copy number alternations more commonly affected
these loci, particularly for NBS1 (Supplementary Table 9). RNA-
sequencing data were obtained from primary female breast
cancer specimens (n= 1080) from the TGCA breast cancer project
and was stratified on the basis of quartile expression of MRE11,
RAD50 and NBS1 and differentially expressed genes (DEGs)
identified. This analysis identified 2591 significantly (>2-fold
Fig. 2 MRN protein expression and survival. a Kaplan–Meier curve for MRE11 nuclear protein expression and breast cancer-specific survival
(BCSS) in the whole cohort. b Kaplan–-Meier curve for MRE11 nuclear protein expression and BCSS in ER+ cohort. c Kaplan–Meier curve for
MRE11 nuclear protein expression and BCSS in ER− cohort. d Kaplan–Meier curve for RAD50 nuclear protein expression and BCSS in the
whole cohort. e Kaplan–Meier curve for RAD50 nuclear protein expression and BCSS in ER+ cohort. f Kaplan–Meier curve for RAD50 nuclear
protein expression and BCSS in ER− cohort. g Kaplan–Meier curve for NBS1 nuclear protein expression and BCSS in the whole cohort.
h Kaplan–Meier curve for NBS1 nuclear protein expression and BCSS in ER+ cohort. i Kaplan–Meier curve for NBS1 nuclear protein expression
and BCSS in ER− cohort.
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change, p adj < 0.05) DEGs between patients with low as
compared to high MRE11 expression, 9768 DEGs between patients
with low vs high RAD50 expression and 3528 DEGs between
patients with low vs high NBS1/NBN (Fig. 4a–c and Supplementary
Data 2, 3 and 4). We identified significantly enriched Kyoto
Encyclopaedia of Genes and Genomes “KEGG” pathways (Supple-
mentary Tables 10–12), notably in the context of this study
including pathways related to pentose metabolism and steroid
biosynthesis (hsa00040, hsa00140) associated with MRE11 (Sup-
plementary Table 10); immune function and surveillance
(hsa04060, hsa04657, hsa04650) associated with RAD50 (Supple-
mentary Table 11); and lipid metabolism, mitochondrial function
and inflammatory mediators (hsa04975, hsa00590, hsa04657)
associated with NBS1 expression (Supplementary Table 12). We
also examined the chromosomal location distribution of DEGs and
identified significantly enriched chromosomal locations for DEGs
associated with RAD50 and NBS1 (Supplemental Table 14).
We next identified genes commonly DEGs in patients with low
or high expression of MRE11, RAD50 and NBS1 (Fig. 4d, e). This
identified 77 genes with higher expression in patients with high
(Q4) expression of MRE11, RAD50 and NBS1, whereas there were
545 genes with higher expression in patients with low (Q1)
expression of MRE11, RAD50 and NBS1. Whereas non-coding genes
were abundant among these 77 genes and thus no statistically
significant pathways are enriched, key pathways were statistically
significantly enriched amongst the 545 genes, including genes
involved in oxidative phosphorylation (hsa00190) (Supplemental
Table 13). Notably, these 545 genes commonly associated with
low MRN were enriched in pathways related to mitochondrial
dysfunction, including expression of seven key genes encoding
components of complex I (NDUFA3, NDUFA4L2, NDUFA13,
NDUFB7), complex IV (COX4I2, COX7A1) and complex V (the ATP
synthase component ATP5F1D) (Fig. 4d–f).
DISCUSSION
The MRN complex is critical for genomic stability1–3. Impaired MRN
activity can promote a mutator phenotype18, thereby leading to
malignant transformation. Germline mutations of MRN leading to
breast cancer (and other tumours) have been reported albeit
extremely rare7–9. MRE11 and RAD50 are considered as moderate
susceptibility genes for breast cancer19. Polymorphic variants of
MRE11, RAD50 or NBS1 may also increase the risk of development
of breast cancer10,11,20. In the current study, we have conducted a
comprehensive investigation of MRN in sporadic breast cancers.
Low MRN is linked with high tumour grade, high mitotic index,
Fig. 3 MRN transcripts and survival. a Kaplan–-Meier curve for RAD50 mRNA expression and breast cancer-specific survival (BCSS) in the
whole cohort. b Kaplan–Meier curve for RAD50 mRNA expression and BCSS in ER+ cohort. c Kaplan–Meier curve for RAD50 mRNA expression
and BCSS in ER− cohort. d Kaplan–Meier curve for has-miR-99b expression and BCSS in the whole cohort. e Kaplan–Meier curve for has-miR-
99b expression and BCSS in ER+ cohort. f Kaplan–Meier curves for has-miR-99b expression and BCSS in ER− cohort. g Kaplan–Meier curves for
has-miR-494 expression and BCSS in the whole cohort. h Kaplan–Meier curve for has-miR-494 expression and BCSS in ER+ cohort.
i Kaplan–Meier curve for has-miR-494 expression and BCSS in ER− cohort.
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ER- and high-risk NPI. Univariate analysis showed an adverse
prognostic significance for low nuclear MRE11 and low nuclear
RAD50 expression. In multivariate analysis, low nuclear RAD50
remained independently associated with poor survival. However, a
limitation of our study is that patients in this historical cohort
(1986–1999) received cyclophosphamide/methotrexate/5-flurour-
acil (CMF)-based chemotherapy. To further validate the prognos-
tic/predictive significance of MRE11, additional studies in patient
who received more modern DNA-damaging chemotherapy will be
required. At the transcriptomic level, in both whole cohorts, only
low RAD50 mRNA remained associated with poor survival.
Interestingly, in sub-group analysis, in cohort 1 (n= 1809) low
RAD50 mRNA was significantly associated with poor survival in
ER− cohort but not in ER+ cohort. In cohort 2 (n= 4904), on the
other hand, low RAD50 mRNA was significantly associated with
poor survival in ER+ cohort but not in ER− cohort. We speculate
Fig. 4 MRN and genome-wide alterations. Differentially expressed genes (DEGs) were identified using RNAseq data from the TCGA-BRCA
cohort dichotomized on the basis of low (quartile 1) versus high (quartile 4) expression of MRE11 (a), RAD50 (b) and NBN/NBS1 (c). We next
identified DEGs that were low (77 genes) or higher (545 genes) in patients with lower expression of MRN components (d–f) and identified
enriched KEGG pathways (d, e). Pathways related to mitochondrial dysfunction were associated with reduced MRN expression (f).
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6
npj Breast Cancer (2021)   143 Published in partnership with the Breast Cancer Research Foundation
that this difference in ER+ and ER− tumours in both cohorts could
be related to patient populations receiving different types of
chemotherapy and/or endocrine therapy. Nevertheless, a limita-
tion in our study is that we were not able to transcriptionally
profile our cohort to further validate protein expression data.
In a mice model of sporadic breast tumorigenesis, disruption of
MRE11 (which also disrupts the stability of MRN complex) was
shown to promote the progression of mammary hyperplasia into
invasive cancer. On the other hand, functional MRE11 prevented
cancerous transformation in that study21. Our data suggest that
low nuclear MRN may impair DNA repair function and promote an
aggressive ‘mutator phenotype’ breast cancers. Interestingly, we
observed cytoplasmic staining for MRE11 and NBS1, but only
nuclear expression status influenced histopathological pheno-
types and survival. Although the mechanisms of dysfunctional
localization for MRE11 and NBS1 observed here is not yet known,
it is possible that cytoplasmic staining may also indicate
mitochondrial localization. MRE11 has previously been shown to
translocate to mitochondrial following reactive oxygen stress-
induced mitochondrial DNA damage22. In another study of MRN
expression in breast cancers, the authors reported reduced RAD50
(3%), MRE11 (7%) and NBS1 (10%) protein expression, particularly
in triple-negative disease, high-grade tumours and in familial
breast cancers23. RAD50, MRE11 and NBS1 gene sequencing in
eight patients from non-BRCA1/2 breast cancer families whose
tumours also showed low/loss of RAD50, MRE11 and NBS1
revealed two germline mutations in MRE11, specifically, a
missense mutation R202G and a truncating mutation R633STOP
(R633X)23. Moreover, NBS1 deficiency was associated with poor
survival in that study23. In the current study, we not only observed
low nuclear expression of MRN, but a small proportion of tissue
microarray (TMA) cores also had complete loss of MRN expression:
MRE11 (14%), RAD50 (5%) and NBS1 (9%). However, a limitation
here is that we did not confirm the complete loss of MRN
expression in whole tumour sections. Another limitation is that
sequence data was unavailable for MRE11, RAD50 or NBS1 in these
specific patients and it was not possible to investigate in patients
with familial breast cancers. Nevertheless, our data concur with
those reported by Bartkova et al.23 demonstrating adverse
features in tumour with low MRN levels.
Our study also suggests that the mechanism for low expression
of MRN in breast cancers is likely to be multifactorial. MicroRNA
regulation, mRNA expression and stability combined with post-
translational control could all influence MRN expression13.
Interestingly, overexpression of hsa-miR-494 and hsa-miR-99b that
regulate transcription of MRN was associated with poor clinical
outcomes in the current study. At the transcriptomic level,
however, only low RAD50 mRNA expression remained associated
with poor survival in the current study. In multivariate analyses,
RAD50 protein loss remained independently associated with poor
survival. RAD50, which belongs to the structural maintenance of
the chromosome protein family, is the largest subunit of MRN1–3.
The homozygous mutation in the Zn-hook domain of RAD50 is
embryonically lethal in mice. The heterozygous mutation can
promote liver tumorigenesis. Alteration in the level of RAD50 has
been reported in acute myeloid leukaemia, Burkitt lymphoma
and endometrial carcinoma1. Together, the data imply that
RAD50 status may aid prognostic stratification of patients in
various cancers including sporadic breast cancers.
Given the multifunctional role of MRN in the maintenance of
cellular homeostasis, we speculated that MRN deficiency could
have an impact at a genome-wide level and influence aggressive
phenotypes in sporadic breast cancer. Pathway analysis of genes
associated with MRE11 in breast cancer patients identified
significantly enriched pathways associated with steroid hormone
biosynthesis, metabolic pathways, ascorbate and aldarate meta-
bolism, complement and coagulation and retinol metabolism.
Of interest, the UDP glucronosyltransferase (UGT) family and
aldo–keto reductase family were present in these pathways. In
cancer, UGTs have altered expression and are linked to drug
resistance24–26. Furthermore, from the IHC findings that showed
both low levels of MRE11 and RAD50 were linked with higher
grade tumours, the identification of aldo–keto reductase family in
both RAD50 low and MRE11 low tumours highlights a role in
tumour progression. AKR1B10 was significantly up-regulated
(4-fold change FDR < 0.05) in MRE11 low tumours. ARK1B10 has
been shown to be involved tumour progression and metastasis27.
DEGs associated with high NBS1 identified enriched chromosomal
locations including chromosome 8 including the NBS1 locus itself.
Genes involved in cell cycle (CCNB3, CCNE2, E2F5), IDO1, IFNG and
PGR were all up-regulated, consistent with the clinical parameters
identified with high NBS1 levels by IHC. IDO1 has been shown to
play a role in breast tumour dormancy, which is an important step
in invasive ductal carcinoma28. We also identified three signifi-
cantly enriched pathways (FDR < 0.05), fat digestion and absorp-
tion, Ras signalling pathway and arachidonic acid metabolism.
PLA2 genes in arachidonic acid metabolism have been shown to
play a role in the mammalian target of rapamycin signalling in
breast cancer29. While Ras is not commonly mutated in breast
cancer, Ras signalling is often up-regulated by other mechan-
isms30. A recent study identified that up-regulation of H-RAS, K-RAS
and N-RAS in primary breast cancers was linked to different clinical
parameters, with H-RAS up-regulation correlating with larger
tumour size31. We identified up-regulation of H-RAS (>2-fold,
FDR < 0.05) in tumours that had low NBS1 expression. Interest-
ingly, low NBS1 protein expression correlated with larger tumour
size, suggesting that NBS1 shows a negative correlation with
H-RAS signalling. Analysis of DEGs identified in patients with low
versus high RAD50 expression identified 21 significantly enriched
KEGG pathways. Notably, the expression of the ESR1 gene, which
encodes ERα was significantly lower in patients with low RAD50
expression. This is consistent with our findings from IHC that low
RAD50 correlated with ER− (FDR < 0.001). IHC also indicated that
low RAD50 is associated with poor outcomes/more progressed
cancer–lower BCSS, high-grade, high-risk NPI and high mitotic
index. In addition to pathways related to inflammation and
immune response, JAK-STAT signalling pathway was also sig-
nificantly over-represented, which indicates potential proliferation,
differentiation and anti-apoptotic effects.
Finally, our analysis of DEGs associated with low expression of
MRE11, RAD50 and NBS1 identified increased expression of seven
genes associated with mitochondrial dysfunction and metabolic
reprogramming in cancer. Interestingly, these are nuclear-
encoded and five (ATP5F1D, NDUFB7, COX7A1, NDUFA3, NDUFA13)
of the seven genes are encoded on chromosome 19, with
NDUFA4L2 and COX4I2 encoded on chromosomes 12 and 20,
respectively. While chromosome 19 harbours the highest gene
density in the human genome32, the association of these key
nuclear-encoded mitochondrial-associated genes with MRN
expression may be functionally related. Thus, although aberrant
reduced expression of each MRN component is associated with
specific pathways (Supplemental Tables S8–10), reduced expres-
sion collectively of MRE11, RAD50 and NBS1 converge with
increased expression of key nuclear-encoded mitochondrial
proteins (Fig. 4g). Whereas the precise functions of NDUFA3,
NDUFA13 (also called GRIM19), COX7A1, COX4I2 and ATP5F1D in
oxidative phosphorylation remain somewhat poorly understood,
increased expression of NDUFA4L2 is known to drive pro-
oncogenic phenotypes in numerous cancer types. NDUFA4L2 is
implicated in advanced kidney33 and liver34 cancers and functions
in hypoxia-inducible factor-1α (HIF1α)-induced mitochondrial
reprogramming and attenuation of oxidative phosphorylation35.
This raises the intriguing possibility that aberrant mitochondrial
function may contribute to reduced expression of the MRN
complex and thereby contribute to poorer outcomes in breast
A. Alblihy et al.
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cancers. However, detailed mechanistic studies will be required to
explore this hypothesis in detail.
More recently, the MRN complex has also emerged as a target
for synthetic lethality and precision medicine1. MRE11 deficient in
endometrial cancer cells36 and colorectal cancer cells37,38 have
been shown to be sensitive to PARP inhibitors. The data presented
in the current clinical study would, therefore, also indicate that
MRN-deficient sporadic breast cancers may also be suitable for
such a synthetic lethality approach.
METHODS
MRN complex protein expression
The clinical study was performed in a consecutive series of 1650 patients
with primary invasive breast carcinomas who were diagnosed between
1986 and 1999 and entered into the Nottingham Tenovus Primary Breast
Carcinoma series. Patient demographics are summarized in Supplementary
Table 1. This is a well-characterized series of patients with long-term
follow-up that we have investigated in a wide range of biomarker
studies39–42. All patients were treated in a uniform way in a single
institution with standard surgery (mastectomy or wide local excision) with
radiotherapy. Prior to 1989, patients did not receive systemic adjuvant
treatment (AT). After 1989, AT was scheduled based on prognostic and
predictive factor status, including NPI, ER status, and menopausal status.
Patients with NPI scores of <3.4 (low risk) did not receive AT. In this
historical cohort, for pre-menopausal patients with NPI scores of ≥3.4 (high
risk), classical CMF chemotherapy was given; patients with ER+ tumours
were also offered endocrine therapy. Postmenopausal patients with NPI
scores of ≥3.4 and ER positivity were offered endocrine therapy, while ER−
patients received classical CMF chemotherapy. Median follow-up was
111 months (range 1–233 months). Overall survival data were maintained
on a prospective basis. BCSS was defined as the number of months from
diagnosis to the occurrence of BC-related death. Survival was censored if
the patient was still alive at the time of analysis, lost to follow-up, or died
from other causes.
Tumour Marker Prognostic Studies (REMARK) criteria, recommended by
McShane et al.43 were followed throughout this study. Ethical approval was
obtained from the Nottingham Research Ethics Committee (C202313).
Informed consent was obtained from all human participants.
TMA and IHC
TMAs were constructed and immunohistochemically profiled for MRE11,
RAD50 and NBS1. A set of slides were incubated for 18 h at 4 °C with the
primary mouse monoclonal anti-MRE11 antibody (ab214, Abcam), at a
dilution of 1:800. A further set of slides were incubated for 18 h at 4 °C with
the primary mouse monoclonal anti-RAD50 antibody (Ab489, Abcam), at a
dilution of 1:100. A further set of slides were incubated for 18 h at 4 °C with
the primary rabbit monoclonal anti-NBS1 antibody (N3162, Sigma), at a
dilution of 1:100. We have also profiled a panel of DNA repair markers
including those involved in DSB repair (BRCA1, BRCA2, ATM, CHK2, ATR,
Chk1, pChk1, RAD51, γH2AX, RPA1, RPA2, DNA-PKcs), RECQ helicases (BLM,
WRN, RECQ1, RECQL4, RECQ5), nucleotide excision repair (ERCC1) and base
excision repair (SMUG1, APE1, FEN1, PARP1, XRCC1, Pol β). Primary
antibodies, clone, source and optimal dilution for each immunohisto-
chemical marker were published previously40,42,44–55 and also summarized
in Supplementary Table 2.
We validated MRE11, RAD50 and NBS1 antibodies by western blots in a
panel of breast cancer cell lines (Fig. 1a). In addition, transient knockdown
of MRE11 (manuscript under submission), RAD50 and NBS1 using small
interfering RNAs have been performed previously56,57 to confirm the
validity of the antibody used in the current IHC study. Negative controls for
IHC included omission of the primary antibody and IgG-matched serum.
Positive control included normal lymphoid (lymph node/spleen) tissue
within the TMA. We have previously published the validity of all other
markers used in the current study40,42,44–55.
Evaluation of immune staining
The whole field inspection of the core was scored and intensities of the
subcellular localization of each marker was identified (nuclear, cytoplasm,
cell membrane). Intensities of subcellular compartments were each
evaluated and grouped as follows: 0= no staining, 1=weak staining, 2
=moderate staining and 3= strong staining. The percentage of each
category was estimated (0–100%). H-score (range 0–300) was calculated by
multiplying the intensity of staining and percentage staining. Not all cores
within the TMA were included for IHC analysis due to missing cores or the
absence of tumour cells. The scoring system used for each immunohis-
tochemical marker is summarized in Supplementary Table 2.
Statistical analyses
Data were performed using SPSS (SPSS, version 17, Chicago, IL). Where
appropriate, Pearson’s χ2, Fisher’s exact, χ2 for trend, Student’s t test and
analysis of variance one-way tests were performed using SPSS software
(SPSS, version 17, Chicago, IL). Cumulative survival probabilities were
estimated using the Kaplan–Meier method. Differences between survival
rates were tested for significance using the log-rank test. Multivariate
analysis was performed using the Cox hazard model. The proportional
hazards assumption was tested using standard log–log plots. Each variable
was assessed in the univariate analysis as a continuous and categorical
variable and the two models were compared using an appropriate
likelihood ratio test. Hazard ratios and 95% confidence intervals were
estimated for each variable. Correlation between levels of MRE11, NBS1
and RAD50 protein expressions and other DNA repair biomarkers were
generated using RStudio software. The correlation was considered
significant at the 0.01 level (two-tailed).
Transcriptomic and miRNA analyses
Prognostic significance of MRE11 mRNA (probe ID 205395_s_at), RAD50
mRNA (probe ID _209349_at) and NBS1 mRNA (probe ID _202907_s_at) was
evaluated in a publicly available microarray dataset from 1809 breast
cancer patients (cohort 1)58. For additional evaluation, an Affymetric
microarray dataset from 4904 breast tumours (cohort 2) was evaluated for
MRE11 mRNA (median probe data), RAD50 mRNA (median probe data) and
NBS1 mRNA (median probe data)59. Prognostic significance miRNAs (hsa-
miR-494 and hsa-miR-99b) involved in the regulation of MRE11, RAD50 and
NBS1 mRNA expression was evaluated in a publicly available miRNA
expression dataset from 2178 breast cancer patients60.
We next analysed the TCGA breast cancer (BRCA) dataset16,17 to identify
copy number and protein-coding variants affecting MRE11, RAD50 and
NBS1, and to identify DEGs in breast cancer patients expressing low
(quartile 1) and high (quartile 4) levels of MRE11, RAD50 and NBS1. To this
end, the presence of coding variants (including missense, frameshifts and
in-frame deletions) affecting the MRE11, RAD50 and NBS1 loci were
assessed in primary female breast cancer specimens (n= 1090) obtained
from the TCGA breast cancer dataset. Rare protein-coding variants were
identified in MRE11 (n= 7), RAD50 (n= 6) and NBS1 (n= 3). One patient
(TCGA-D8-A1J8) harboured mutations in two of the genes (TCGA-D8-A1J8:
MRE11 and RAD50).
Separately, RNAseq expression data (HTseq counts) for primary female
breast cancer specimens were obtained from the GDC (https://portal.gdc.
cancer.gov/) and were dichotomized into low (quartile 1) and high
(quartile 4) based on normalized expression (FPKM) of MRE11, RAD50 and
NBS1 obtained from the Xena browser61 and DEGs identified using
DESeq262. Genes were considered significantly differential expression
where fold changes ±2 and FDR < 0.05. Pathway analysis of significant
DEGs was conducted using WebGestalt63 to interrogate the KEGG database
and chromosomal locations. Copy number variants were assessed using
the cBioPortal64 and expression data in counts format was accessed using
the GDC portal65.
Western blot analysis
A panel of breast cancer cells [MCF-7 (ER+, luminal A), ZR-75-1 (ER+,
luminal B), SKBR3 (HER2+), MDA-MB-231 (triple-negative)] were harvested
and lysed in RIPA buffer (R0278, Sigma) with the addition of protease
cocktail inhibitor (P8348, Sigma), phosphatase inhibitor cocktail 2 (P5726,
Sigma) and phosphatase inhibitor cocktail 3 (P0044, Sigma) and stored at
−20 °C. Protein was quantified using BCA Protein Assay Kit (23227, Thermo
Fisher). Membranes were incubated with primary antibodies as follows:
anti-MRE11(1:500, ab214, Abcam), anti-RAD50 (1:500, ab89, Abcam) and
anti-NBS1 (1:500, N3162, Sigma) at 4 °C overnight. Samples then were
washed and incubated with glyceraldehyde 3-phosphate dehydrogenase
(1:1000, ab9485) at room temperature for 1 h. Membranes were then
washed and incubated with infrared dye-labelled secondary antibodies (Li-
Cor) [IRDye 800CW donkey anti-rabbit IgG (926-32213) and IRDye 680CW
donkey anti-mouse IgG (926-68072)] at dilution of 1:10,000 for 60min. The
Li-Cor Odyssey Imaging System was utilized for scanning membranes.
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For quantifying the bands, the Image Studio Lite software (ver 3.1) (Li-Cor,
USA) was used. The detected band intensity for the proteins of interest
as well as housekeeping gene band intensity was quantified in LI-COR
software.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
Data supporting the study can be found in the Supplementary information file, and
the corresponding author can make any materials available upon request. Aggregate
data from the referenced datasets are available from the corresponding author on
reasonable request. Primary datasets generated during the study are available in
Supplementary Tables 11, 12 and 13. Referenced datasets analysed in the study are
described in ‘Methods’ and accession codes are as follows: E-MTAB-365, E-TABM-43,
GSE11121, GSE12093, GSE12276, GSE1456, GSE16391, GSE16446, GSE16716,
GSE17705, GSE17907, GSE18728, GSE19615, GSE20194, GSE20271, GSE2034,
GSE20685, GSE20711, GSE21656, GSE22093, GSE25066, GSE2603, GSE26971,
GSE29044, GSE2090, GSE31448, GSE32646, GSE3494, GSE36771, GSE37946,
GSE41998, GSE43358, GSE43365, GSE45255, GSE4611, GSE46184, GSE46184,
GSE48390, GSE50948, GSE5327, GSE58812, GSE61304, GSE65194, GSE6532,
GSE69031, GSE7390, GSE76275, GSE78958, GSE9195, GSE 19783 and GSE 40267.
Received: 6 May 2021; Accepted: 22 October 2021;
REFERENCES
1. Bian, L., Meng, Y., Zhang, M. & Li, D. MRE11-RAD50-NBS1 complex alterations and
DNA damage response: implications for cancer treatment. Mol. Cancer 18, 169
(2019).
2. Rein, K. & Stracker, T. H. The MRE11 complex: an important source of stress relief.
Exp. Cell Res. 329, 162–169 (2014).
3. Syed, A. & Tainer, J. A. The MRE11-RAD50-NBS1 complex conducts the orches-
tration of damage signaling and outcomes to stress in DNA replication and
repair. Annu. Rev. Biochem. 87, 263–294 (2018).
4. Wang, Q. et al. Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the
cellular response to DNA double-strand breaks. EMBO J. 33, 862–877 (2014).
5. Carson, C. T. et al. The Mre11 complex is required for ATM activation and the G2/
M checkpoint. EMBO J. 22, 6610–6620 (2003).
6. Lee, J. H. & Paull, T. T. ATM activation by DNA double-strand breaks through the
Mre11-Rad50-Nbs1 complex. Science 308, 551–554 (2005).
7. Chrzanowska, K. H., Gregorek, H., Dembowska-Bagińska, B., Kalina, M. A. & Dig-
weed, M. Nijmegen breakage syndrome (NBS). Orphanet J. Rare Dis. 7, 13 (2012).
8. Waltes, R. et al. Human RAD50 deficiency in a Nijmegen breakage syndrome-like
disorder. Am. J. Hum. Genet. 84, 605–616 (2009).
9. Stewart, G. S. et al. The DNA double-strand break repair gene hMRE11 is mutated
in individuals with an ataxia-telangiectasia-like disorder. Cell 99, 577–587 (1999).
10. Hsu, H. M. et al. Breast cancer risk is associated with the genes encoding the DNA
double-strand break repair Mre11/Rad50/Nbs1 complex. Cancer Epidemiol. Bio-
mark. Prev. 16, 2024–2032 (2007).
11. Heikkinen, K. et al. RAD50 and NBS1 are breast cancer susceptibility genes
associated with genomic instability. Carcinogenesis 27, 1593–1599 (2006).
12. Lu, M. et al. Association between the NBS1E185Q polymorphism and cancer risk:
a meta-analysis. BMC Cancer 9, 124 (2009).
13. Espinosa-Diez, C. et al. MicroRNA regulation of the MRN complex impacts DNA
damage, cellular senescence, and angiogenic signaling. Cell Death Dis. 9, 632
(2018).
14. Paull, T. T. & Lee, J. H. The Mre11/Rad50/Nbs1 complex and its role as a DNA
double-strand break sensor for ATM. Cell Cycle 4, 737–740 (2005).
15. Stracker, T. H., Roig, I., Knobel, P. A. & Marjanovic, M. The ATM signaling network
in development and disease. Front. Genet. 4, 37 (2013).
16. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast
tumours. Nature 490, 61–70 (2012).
17. Ciriello, G. et al. Comprehensive molecular portraits of invasive lobular breast
cancer. Cell 163, 506–519 (2015).
18. Loeb, L. A. Human cancers express mutator phenotypes: origin, consequences
and targeting. Nat. Rev. Cancer 11, 450–457 (2011).
19. Kleibl, Z. & Kristensen, V. N. Women at high risk of breast cancer: molecular
characteristics, clinical presentation and management. Breast 28, 136–144 (2016).
20. Damiola, F. et al. Rare key functional domain missense substitutions in MRE11A,
RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast
Cancer Family Registry case-control mutation-screening study. Breast Cancer Res.
16, R58 (2014).
21. Gupta, G. P. et al. The Mre11 complex suppresses oncogene-driven breast
tumorigenesis and metastasis. Mol. Cell 52, 353–365 (2013).
22. Dmitrieva, N. I., Malide, D. & Burg, M. B. Mre11 is expressed in mammalian
mitochondria where it binds to mitochondrial DNA. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 301, R632–R640 (2011).
23. Bartkova, J. et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor
complex in human breast cancer: MRE11 as a candidate familial cancer-
predisposing gene. Mol. Oncol. 2, 296–316 (2008).
24. Dates, C. R. et al. Human UDP-glucuronosyltransferases: effects of altered
expression in breast and pancreatic cancer cell lines. Cancer Biol. Ther. 16,
714–723 (2015).
25. Landmann, H. et al. UDP glucuronosyltransferase 1A expression levels determine
the response of colorectal cancer cells to the heat shock protein 90 inhibitor
ganetespib. Cell Death Dis. 5, e1411 (2014).
26. Osborne, M. J., Coutinho de Oliveira, L., Volpon, L., Zahreddine, H. A. & Borden, K.
L. B. Overcoming drug resistance through the development of selective inhibitors
of UDP-glucuronosyltransferase enzymes. J. Mol. Biol. 431, 258–272 (2019).
27. Huang, C. et al. AKR1B10 promotes breast cancer metastasis through integrin
alpha5/delta-catenin mediated FAK/Src/Rac1 signaling pathway. Oncotarget 7,
43779–43791 (2016).
28. Lopes-Bastos, B. et al. Association of breast carcinoma growth with a non-
canonical axis of IFNgamma/IDO1/TSP1. Oncotarget 8, 85024–85039 (2017).
29. Wen, Z. H. et al. Critical role of arachidonic acid-activated mTOR signaling in
breast carcinogenesis and angiogenesis. Oncogene 32, 160–170 (2013).
30. Way, G. P. et al. Machine learning detects pan-cancer Ras pathway activation in
The Cancer Genome Atlas. Cell Rep. 23, 172–180 e173 (2018).
31. Banys-Paluchowski, M. et al. Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA
expression in primary breast cancer patients. Breast Cancer Res. Treat. 179,
403–414 (2020).
32. Grimwood, J. et al. The DNA sequence and biology of human chromosome 19.
Nature 428, 529–535 (2004).
33. Minton, D. R. et al. Role of NADH dehydrogenase (ubiquinone) 1 alpha sub-
complex 4-like 2 in clear cell renal cell carcinoma. Clin. Cancer Res. 22, 2791–2801
(2016).
34. Sarathi, A. & Palaniappan, A. Novel significant stage-specific differentially
expressed genes in hepatocellular carcinoma. BMC Cancer 19, 663 (2019).
35. Tello, D. et al. Induction of the mitochondrial NDUFA4L2 protein by HIF-1alpha
decreases oxygen consumption by inhibiting complex I activity. Cell Metab. 14,
768–779 (2011).
36. Koppensteiner, R. et al. Effect of MRE11 loss on PARP-inhibitor sensitivity in
endometrial cancer in vitro. PLoS ONE 9, e100041 (2014).
37. McPherson, L. A., Shen, Y. & Ford, J. M. Poly (ADP-ribose) polymerase inhibitor LT-
626: Sensitivity correlates with MRE11 mutations and synergizes with platinums
and irinotecan in colorectal cancer cells. Cancer Lett. 343, 217–223 (2014).
38. Vilar, E. et al. MRE11 deficiency increases sensitivity to poly(ADP-ribose) poly-
merase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 71,
2632–2642 (2011).
39. Ali, R. et al. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic
epithelial ovarian cancers. Cancer Lett. 469, 124–133 (2020).
40. Ali, R. et al. Targeting PARP1 in XRCC1-deficient sporadic invasive breast cancer or
preinvasive ductal carcinoma in situ induces synthetic lethality and chemopre-
vention. Cancer Res. 78, 6818–6827 (2018).
41. Green, A. R. et al. Clinical impact of tumor DNA repair expression and T-cell
infiltration in breast cancers. Cancer Immunol. Res. 5, 292–299 (2017).
42. Sultana, R. et al. Targeting XRCC1 deficiency in breast cancer for personalized
therapy. Cancer Res. 73, 1621–1634 (2013).
43. McShane, L. M. et al. Reporting recommendations for tumor marker prognostic
studies (REMARK). J. Natl Cancer Inst. 97, 1180–1184 (2005).
44. Savva, C. et al. Werner syndrome protein expression in breast cancer. Clin. Breast
Cancer 21, 57–73 e57 (2021).
45. Alshareeda, A. T. et al. Clinical and biological significance of RAD51 expression in
breast cancer: a key DNA damage response protein. Breast Cancer Res.Treat. 159,
41–53 (2016).
46. Alsubhi, N. et al. Chk1 phosphorylated at serine345 is a predictor of early local
recurrence and radio-resistance in breast cancer. Mol. Oncol. 10, 213–223 (2016).
47. Al-Kaabi, M. M. et al. Checkpoint kinase1 (CHK1) is an important biomarker in
breast cancer having a role in chemotherapy response. Br. J. Cancer 112, 901–911
(2015).
48. Arora, A. et al. Transcriptomic and protein expression analysis reveals clin-
icopathological significance of bloom syndrome helicase (BLM) in breast cancer.
Mol. Cancer Ther. 14, 1057–1065 (2015).
A. Alblihy et al.
9
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2021)   143 
49. Green, A. R. et al. Biological and clinical significance of PARP1 protein expression
in breast cancer. Breast Cancer Res. Treat. 149, 353–362 (2015).
50. Abdel-Fatah, T. M. et al. Untangling the ATR-CHEK1 network for prognostication,
prediction and therapeutic target validation in breast cancer. Mol. Oncol. 9,
569–585 (2015).
51. Albarakati, N. et al. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-
PKcs blockade either alone or in combination with cisplatin for personalized
therapy. Mol. Oncol. 9, 204–217 (2015).
52. Abdel-Fatah, T. M. et al. Genomic and protein expression analysis reveals flap
endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer. Mol.
Oncol. 8, 1326–1338 (2014).
53. Abdel-Fatah, T. M. et al. DNA polymerase beta deficiency is linked to aggressive
breast cancer: a comprehensive analysis of gene copy number, mRNA and pro-
tein expression in multiple cohorts. Mol. Oncol. 8, 520–532 (2014).
54. Abdel-Fatah, T. M. et al. Clinicopathological significance of human apurinic/
apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive
breast cancer. Breast Cancer Res. Treat. 143, 411–421 (2014).
55. Abdel-Fatah, T. M. et al. Single-strand selective monofunctional uracil-DNA gly-
cosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts
response to adjuvant therapy. Breast Cancer Res. Treat. 142, 515–527 (2013).
56. Alblihy, A. et al. RAD50 deficiency is a predictor of platinum sensitivity in sporadic
epithelial ovarian cancers. Mol. Biomed. 1, 2–10 (2020).
57. Alblihy, A. et al. Clinicopathological and functional evaluation reveal NBS1 as a pre-
dictor of platinum resistance in epithelial ovarian cancers. Biomedicines 9, 56 (2021).
58. Gyorffy, B. et al. An online survival analysis tool to rapidly assess the effect of
22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Breast Cancer Res. Treat. 123, 725–731 (2010).
59. Jezequel, P. et al. bc-GenExMiner: an easy-to-use online platform for gene prognostic
analyses in breast cancer. Breast Cancer Res. Treat. 131, 765–775 (2012).
60. Lanczky, A. et al. miRpower: a web-tool to validate survival-associated miRNAs
utilizing expression data from 2178 breast cancer patients. Breast Cancer Res.
Treat. 160, 439–446 (2016).
61. Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the
Xena platform. Nat. Biotechnol. 38, 675–678 (2020).
62. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
63. Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z. & Zhang, B. WebGestalt 2019: gene set analysis
toolkit with revamped UIs and APIs. Nucleic Acids Res. 47, W199–W205 (2019).
64. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
65. Grossman, R. L. et al. Toward a shared vision for cancer genomic data. N. Engl. J.
Med. 375, 1109–1112 (2016).
AUTHOR CONTRIBUTIONS
A.A and A.S. are co-first authors. A.A., A.S., M.S.T., M.A., T.A.-F., J.S. and A.G. performed
research and analysed results; A.E.H., J.N.J. and N.P.M. performed bioinformatics
analysis; S.Y.T, A.G., N.P.M., E.A.R. and S.M. designed research and supervised this
study; A.A., N.P.M. and S.M. wrote the paper. All authors contributed to drafting the
manuscript, read and approved the final completed version.
COMPETING INTERESTS
The authors declare no competing interests.
ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41523-021-00350-5.
Correspondence and requests for materials should be addressed to Srinivasan
Madhusudan.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
A. Alblihy et al.
10
npj Breast Cancer (2021)   143 Published in partnership with the Breast Cancer Research Foundation
